country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-181877

Copy Link Print Information

IHCH-3185

IHCH-3185 is an orally active class I HDAC inhibitor (HDAC1 IC₅₀ =102.9 nM) and A_2AR antagonist (A_2AR K_i =7.6 nM). IHCH-3185 reverses immune gene silencing by inducing histone acetylation and blocks the adenosine signaling pathway to relieve T-cell suppression. IHCH-3185 exhibits antiproliferative activity, induces cell cycle arrest, and significantly improves the tumor microenvironment. IHCH-3185 reduces the proportion of regulatory T cells, increases the CD8⁺/T_reg ratio, and upregulates the expression of key factors such as H2-K1, Cxcl9 and Cxcl10. IHCH-3185 shows significant antitumor potential in CT26 and MC38 mouse tumor models and is suitable for related cancer research.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

화학식: C₂₄H₂₁N₇O₃
분자량:455.47

보관:

Please store the product under the recommended conditions in the Certificate of Analysis.

IHCH-3185 Chemical Structure

사이즈

가격

재고

수량

Amount: USD 0.00

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- 제품 설명
- IC₅₀ & Target
- In Vitro
- Parmacokinetics
- In Vivo
Chemical Information
순도&문서
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

제품 설명

IC₅₀ & Target

HDAC1

102.9 nM (IC₅₀)

A2AR

7.6 nM (Ki)

All HDAC Isoforms :

All Adenosine Receptor Isoforms :

In Vitro

IHCH-3185 (compound 13t) inhibits recombinant human HDAC1 (IC₅₀=102.9 nM, 15 min), exerts moderate inhibitory effects on HDAC2 and HDAC3, and shows no inhibitory activity against HDAC4 or HDAC6 even at concentrations up to 10 μM^[1].
IHCH-3185 inhibits the human A_2AR receptor-mediated cAMP signaling pathway in HEK293-A₂ _AR cells, with an IC₅₀ of 88 nM^[1].
IHCH-3185 exhibits broad-spectrum antiproliferative activity in a variety of human and mouse tumor cell lines, with a GI₅₀ ranging from 0.06 μM (DoHH2) to 1.8 μM (MC38, SK-BR-3)^[1].
IHCH-3185 (0.3-3.0 μM; 48 h) induces G0/G1 phase arrest in a concentration-dependent manner in murine colon cancer cell lines CT26 and HCT-116 following treatment at concentrations of 0.3, 1.0 and 3.0 μM for 48 h^[1].
IHCH-3185 (1.5 nM; 72 h) reverses the inhibitory effect of NECA on IFN-γ secretion in activated mouse splenocytes, with an incubation time of 72 h^[1].
IHCH-3185 (0.3-3.0 μM; 24 h) induces concentration-dependent increases in the levels of acetylated histone H3 and H4 in CT26 and MC38 mouse colon cancer cells following treatment at 0.3, 1.0 and 3.0 μM for 24 h^[1].
IHCH-3185 (1-10 μM; 24 h) upregulates the mRNA expression of H2-K1, Cxcl9 and Cxcl10 in MC38 mouse colon cancer cells in a concentration-dependent manner after 24 h of treatment at 1, 3 and 10 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

CT26, MC38, GP-2d, SW620, HCT-116, T-47D, SK-BR-3, NCI-H1975, PC-9, SU-DHL-4, DoHH2
Concentration:

0.00005-10 μM
Incubation Time:

72 h
Result:

Exhibited broad-spectrum antiproliferative activity with GI₅₀ values of 0.38 μM (CT26), 1.8 μM (MC38), 0.6 μM (GP-2d), 0.6 μM (SW620), 0.2 μM (HCT-116), 0.8 μM (T-47D), 1.8 μM (SK-BR-3), 0.5 μM (NCI-H1975), 0.4 μM (PC-9), 0.5 μM (SU-DHL-4), and 0.06 μM (DoHH2).

Cell Cycle Analysis^[1]

Cell Line:

CT26, HCT-116 mouse colon cancer cell lines
Concentration:

0.3, 1.0, 3.0 μM
Incubation Time:

48 h
Result:

Induced a concentration-dependent G0/G1 phase arrest in both CT26 and HCT-116 cells, with significant increases in G0/G1 population and corresponding decreases in S phase population at all tested concentrations.

Western Blot Analysis^[1]

Cell Line:

CT26, MC38 mouse colon cancer cells
Concentration:

0.3, 1.0, 3.0 μM
Incubation Time:

24 h
Result:

Induced a concentration-dependent increase in acetylated H3 and H4 levels in both CT26 and MC38 cells, confirming functional HDAC inhibition.

Real Time qPCR^[1]

Cell Line:

MC38 mouse colon cancer cells
Concentration:

1-10 μM
Incubation Time:

24 h
Result:

Significantly upregulated mRNA expression of H2-K1 (MHC-I), Cxcl9, and Cxcl10 in a concentration-dependent manner, with fold changes relative to vehicle control of ~2.5 (1 μM), ~3 (3 μM), and ~2.8 (10 μM) for H2-K1; ~2 (1 μM), ~4 (3 μM), and ~2.8 (10 μM) for Cxcl9; and ~2 (1 μM), ~4 (3 μM), and ~2.8 (10 μM) for Cxcl10.

Parmacokinetics

Species	Dose	Route	T_1/2β	T_max	C_max	AUC_0-t	AUC_0-∞	MRT	F	CL	V_dss
Mice^[1]	5 mg/kg	i.v.	1.03 h	/	6279 ng/mL	5474 ng·h/mL	5511 ng·h/mL	0.966 h	/	15.2 mL/min/kg	0.881 L/kg
Mice^[1]	20 mg/kg	p.o.	4.29 h	0.667 h	6911 ng/mL	18605 ng·h/mL	18808 ng·h/mL	3.36 h	85 %	/	/
Mice^[1]	100 mg/kg	p.o.	6.33 h	0.833 h	38617 ng/mL	134817 ng·h/mL	139094 ng·h/mL	4.48 h	126 %	/	/

In Vivo

IHCH-3185 (compound 13t) (120 mg/kg; p.o.; once daily; for 14 consecutive days) exhibits a tumor regression efficiency of 71.1% in a mouse model of MC38^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6 (male); BALB/c^[1]
Dosage:

60-120 mg/kg (MC38 model); 90-120 mg/kg (CT26 model); 20 mg/kg (PK); 100 mg/kg (PK); 5 mg/kg (PK, IV)
Administration:

p.o.; qd; 14 days (antitumor efficacy); p.o. (PK, 20 mg/kg, 100 mg/kg); i.v. (PK, 5 mg/kg)
Result:

Achieved TGI of 47.1% (P < 0.05) at 60 mg/kg, 62.2% (P < 0.01) at 90 mg/kg, and 71.1% (P < 0.001) at 120 mg/kg in MC38 syngeneic model.
Achieved TGI of 50.9% (P < 0.01) at 90 mg/kg and 68.5% (P < 0.001) at 120 mg/kg in CT26 syngeneic model.
Showed high oral bioavailability of 85% at 20 mg/kg and 126% at 100 mg/kg in male C57BL/6 mice.
Reduced intratumoral regulatory T-cell populations and increased the CD8⁺ T-cell/Treg ratio in both CT26 and MC38 models.
Induced histone H3 acetylation in CT26 and MC38 tumor tissues.
Caused no significant body weight loss at all tested doses.

Chemical Information

분자량 455.47
화학식 C₂₄H₂₁N₇O₃
SMILES

NC1=NC(OCCC2=CC=C(C=C2)C(NC3=CC=CC=C3N)=O)=CC4=NC(C5=CC=CO5)=NN41
선적

Room temperature in continental US; may vary elsewhere.
보관

Please store the product under the recommended conditions in the Certificate of Analysis.

순도&문서

Handling Instructions (2659 KB)

References

[1]. Yan W, et al. Pharmacokinetics-Driven Optimization of Immunotherapeutic Agents Targeting the Adenosine A_2A Receptor (A_2AR) and Histone Deacetylases (HDACs). J Med Chem. 2026;69(5):6038-6062. [Content Brief]

Calculators

몰농도 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

농도 희석 계산기

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

MOQ

Minimum order quantity

100 mg

견적 받기 해외재고보유

Other size

견적 받기

Amount: USD 0.00

Biological Activity
- 제품 설명
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
순도&문서
References

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

상품명:
CAS No.:
Species:
Purity:
수량:

IHCH-3185

All HDAC Isoforms

All Adenosine Receptor Isoforms

Biological Activity

Chemical Information

순도&문서

References

Calculators

Help & FAQs

IHCH-3185 Related Classifications

HY-181877 Related Classifications